Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX R&D credit carryforward

R&D credit carryforward at other companies

AZZ logo
AZZAZZ
$970K-80.8%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.89M0.0%
HTF
Heartflow, Inc. Common StockHTFL
$7.63M+7.3%
Nuvation Bio logo
Nuvation BioNUVB
$23.38M+20.6%
Sylvamo logo
SylvamoSLVM
$0-100%
HRO
HarrowHROW
$4.79M+111%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s r&d credit carryforward?
Pacira BioSciences, Inc. (PCRX) reported r&d credit carryforward of $124.6M in Q4 2024.